Podcast appearances and mentions of David T Rubin

The GI Research Foundation was able to produce this podcast with sponsorships from AbbVie and Metro Infusion Center.With David T. Rubin, MD, Joseph B. Kirsner Professor of Medicine; and Ashley Sidebottom, PhD, Research Assistant Professor and Platform Director, Host-Microbe Metabolomics Facility, University of ChicagoStruggling with sleep and inflammatory bowel disease (IBD)? You're not alone. This episode dives deep into the surprising connection between sleep, gut health, Crohn's disease and ulcerative colitis. Join us as we chat with world-renowned experts David T. Rubin, MD, and Ashley Sidebottom, PhD who shed light on the intricate relationship between the microbiome, sleep, and IBD:The science behind the gut-sleep connection in IBDHow metabolites can trigger inflammation and sleep disturbancesTo access other episodes of Visceral: Listen to Your Gut and learn more about the GI Research Foundation's support of clinical and laboratory research to treat, prevent, and cure digestive diseases, please visit https://www.giresearchfoundation.org/.Written and produced by Anna Gomberg. Edited and mixed by Mike Collins-Dowden. Available on Apple Podcasts, Spotify, and everywhere else you listen.This episode is brought to you by AbbVie and Metro Infusion Center.AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas. For more information about AbbVie, please visit us at https://www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube, and LinkedInMetro Infectious Disease Consultants, the parent company of Metro Infusion Centers, is proud to announce their 30th anniversary Gala Celebration on October 26 in downtown Chicago. With 110 physicians and over 220 infusion centers nationwide, we are committed to making life saving therapies available in a comfortable and cost-effective environment, while continuing to support the future generations of infectious disease physicians. Please visit us at www.midcgala.com to learn how you can participate.#podcast #research #metabolites #microbiome #sleepstudy #IBS #IBD #crohns #colitis #hope #mindbody #futureofmedicine

Welcome to our 100th episode! This week we talked to the renowned Dr. David T. Rubin! Dr. Rubin is the Joseph B. Kirsner Professor of Medicine and a Professor of Pathology, Chief of the Section of Gastroenterology, Hepatology & Nutrition and the Co-Director of the Digestive Diseases Center at The University of Chicago Medicine. He also currently serves as an associate faculty member at the MacLean Center for Clinical Medical Ethics, an associate investigator at the University of Chicago Comprehensive Cancer Center and is a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics. He is the chair of the National Scientific Advisory Committee of the Crohn's & Colitis Foundation, where he also serves as a Board of Trustees member. He is the deputy chair of the Executive Committee of the International Organization for the Study of Inflammatory Bowel Disease.  In 2018, Dr. Rubin completed the Harvard T.H. Chan School of Public Health Leadership Development Course for Physicians.Dr. Rubin is a Fellow of the American Gastroenterological Association (AGA), the American College of Gastroenterology (ACG), the American Society for Gastrointestinal Endoscopy (ASGE), the American College of Physicians (ACP), and the Royal College of Physicians (Edinburgh). He is on the Board of Trustees for the ACG. Among numerous awards and honors, Dr. Rubin was chosen by his peers as a member of Best Doctors (recognized for superior clinical ability) and America's Top Physicians (gastroenterology). Additionally, he twice received the ACG's Governor's Award of Excellence in Clinical Research (2003 and 2013), and the UChicago Postgraduate Teaching Award in recognition of significant contributions for fellowship education (2006). In 2012, he received the Crohn's & Colitis Foundation's Rosenthal Award, a national leadership award bestowed upon a volunteer who has contributed in an indisputable way to the quality of life of patients and families. He is an Associate Editor of the journal Gastroenterology and Editor-in-Chief of the ACG On-Line Education Universe. In 2020, Dr. Rubin received the Sherman Prize for Excellence in Crohn's and Colitis.Dr. Rubin is an editor of a best-selling book Curbside Consultation in IBD which is now in its 3rd edition and an author or coauthor of over 500 articles on treatment and management of IBD, cancer in IBD and novel paradigms, as well as the first author of the 2019 ACG Guidelines for ulcerative colitis. His current research is in the area of novel approaches to monitoring of IBD (wearables and point of care intestinal ultrasound), prevention of progressive complications from uncontrolled inflammation, and a variety of collaborative and translational studies related to the causes of IBD and its complications. Episodes from some of Dr. Rubin's UChicago's team: Dr. Alysse Bedell- Gastro PsychologistMichele Rubin, APN- JPouch surgical nurse extraordinaireMarita Kametas- Ostomy Specialist! Dr. David Choi- IBD PharmacistPlease keep in mind that the views and opinions expressed in this program are those of the speakers and should not be considered medical or legal advice. Please consult with your healthcare team on any changes to your disease, diet, or treatment.Let's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

David T. Rubin, MD, AGAF - What They Say and What They Think: Exploring Tools for Assessing Bowel Urgency in Patients with Ulcerative Colitis

David T. Rubin, MD, AGAF - What They Say and What They Think: Exploring Tools for Assessing Bowel Urgency in Patients with Ulcerative Colitis

David T. Rubin, MD, AGAF - What They Say and What They Think: Exploring Tools for Assessing Bowel Urgency in Patients with Ulcerative Colitis

David T. Rubin, MD, AGAF - What They Say and What They Think: Exploring Tools for Assessing Bowel Urgency in Patients with Ulcerative Colitis

Host: Neilanjan Nandi, MD Guest: David T. Rubin, MD With more data emerging on COVID-19 vaccines every day, what do our patients with inflammatory bowel disease need to know about the vaccine currently available? Dr. Neil Nandi will be discussing these updates and how we can keep our patients safe with Dr. David Rubin, Professor of Medicine at the University of Chicago Pritzker School of Medicine.

Host: Neilanjan Nandi, MD Guest: David T. Rubin, MD How has the COVID-19 pandemic impacted patients with IBD? Dr. Neil Nandi is here to answer our COVID-19 questions for our IBD patients with Dr. David Rubin, Professor of Medicine at the University of Chicago Pritzker School of Medicine.

From the beginning of the COVID-19 pandemic, people with inflammatory bowel disease (IBD) have had many questions. Now that vaccines against the virus are becoming available, people living with Crohn's disease or ulcerative colitis need even more information in order to make decisions. I asked Dr David Rubin, Chief of the Section of Gastroenterology, Hepatology & Nutrition and the Co-Director of the Digestive Diseases Center at The University of Chicago Medicine to answer some of these initial questions about the first COVID-19 vaccines (manufactured by Pfizer and Moderna). Topics discussed on this episode include: How vaccines work How mRNA works How IBD medications affect the immune system IBD medications and their potential effect on COVID-19 vaccination When we'll have more information about COVID-19 vaccines and IBD Why side effects with vaccines are expected and what they mean Key Quotes: The first thing is to remember that inflammatory bowel disease itself is a condition where in almost all situations, the immune system is overactive. So having Crohn's disease or ulcerative colitis is not a situation where you're immune deficient. So IBD patients in all the analyses during COVID have not actually been found to be at increased risk for getting infected, or at increased risk for developing COVID as having just because they have Crohn's or colitis or have an ostomy or have a j pouch. The messenger RNA is degraded within a couple days it's out of your system doesn't hang around. It doesn't ever enter the nucleus of cells, it doesn't become a permanent part of your genetic material in your body. And therefore that's why it is thought to be extremely safe. But I want to make it clear to everyone that they didn't just decide to do this in February, March. This was something that actually was in development, it just got pushed through because of the critical nature of the pandemic. ... there are no data to say that vaccination triggers IBD. And it's been looked at carefully in many studies. And there's no data to show that getting a vaccine triggers a relapse of your IBD. And the newer vaccines that we're talking about here, will not do that either. ...we don't know for sure yet is whether you'll have impaired ability to mount a protective immunity at the same level as if you weren't on therapy. But that doesn't mean you won't develop any immunity. And in fact, it's possible that you'll develop the same immunities to general population because the messenger RNA vaccine is a completely new mechanism. Dr Rubin's Tweets and Tweetorials: "I've created a thread that summarizes the statements from the #IOIBD global expert panel about management of #IBD during #COVID19." https://threadreaderapp.com/thread/1247526583985823749.html "Here are my thoughts and a few updates about #SARSCoV2 vaccines, and also about implications for our #IBD patients. A tweetorial in 20 parts." https://threadreaderapp.com/thread/1333972549848469508.html "Terrific @US_FDA presser this morning. The agency has its origins in SAFETY and then EFFICACY became part of their regulatory pathway. Both Director Hahn @SteveFDA and career scientist Dr. Peter Marks @FDACBER used the language "safety and efficacy" (in that order). IMPORTANT." https://twitter.com/IBDMD/status/1337771896721563655 Further Reading: Understanding How Vaccines Work How mRNA Vaccines Work Understanding and Explaining mRNA COVID-19 Vaccines How the Pfizer-BioNTech Vaccine Works (NYT: Paywall) GI Physicians Urge COVID-19 Vaccines for All IBD Patients COVID-19 Vaccines: What IBD Patients & Caregivers Need to Know Getting a COVID-19 Vaccine: What to Know If You’re Immunocompromised Expect Mild Side Effects From COVID-19 Vaccines, CDC Advisory Group Says Doctors for America COVID Vaccine FAQ Toolkit Scholarly Publications: Winter is coming! Clinical, immunological, and practical considerations for vaccinating patients with IBD during the COVID pandemic COVID-19 vaccinations in patients with inflammatory bowel disease Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Find David T. Rubin, MD at The University of Chicago Medicine, Twitter, Rubin Lab, Rubin's Reflections (Blog), and Cornerstones Health. Find Amber J Tresca at AboutIBD.com, Verywell, Facebook, Twitter, Pinterest, and Instagram. Credits: Mix and sound design is by Mac Cooney. Theme music, "IBD Dance Party,” is from ©Cooney Studio.

The new American College of Gastroenterology guideline on ulcerative colitis is discussed by one of its authors, David T. Rubin, MD, from the Inflammatory Bowel Disease Center at the University of Chicago, and Maylyn Martinez, MD, also from the University of Chicago. Related Article(s): Ulcerative Colitis in Adults

Go online to PeerView.com/QDR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has brought substantial advances in the management of IBD. Nevertheless, under current therapeutic options, half of patients with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD) fail to achieve sustained remission. After years of IBD treatment dominated by monoclonal antibodies, we are currently witnessing promising developments of small molecules for UC and CD. Among them, Janus kinase (JAK) inhibitors are a promising new class that have demonstrated efficacy with a favorable safety profile in clinical trials. Utilizing a mix of didactic presentations and prerecorded patient videos, this activity based on a live symposium will explore current and emerging treatments and guidelines for UC and CD. The faculty panel provides a thorough examination of current and emerging JAK inhibitors, as well as insight into patient-centered, treat-to-target management approaches in IBD. Upon completion of this activity, participants should be better able to: Examine the burden of illness and unmet needs in patients with inflammatory bowel disease, Summarize efficacy and safety data related to current and emerging JAK inhibitors for the treatment of Crohn's disease (CD) and ulcerative colitis (UC), Treat CD and UC in accordance with current evidence and guidelines, recognizing the role of non–anti-TNF therapies in inducing and maintaining remission in patients with moderate to severe disease, Incorporate JAK inhibitors into treatment plans for individual patients with CD or UC, recognizing the importance of achieving therapeutic targets and a patient-centered approach to care.

Go online to PeerView.com/QDR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has brought substantial advances in the management of IBD. Nevertheless, under current therapeutic options, half of patients with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD) fail to achieve sustained remission. After years of IBD treatment dominated by monoclonal antibodies, we are currently witnessing promising developments of small molecules for UC and CD. Among them, Janus kinase (JAK) inhibitors are a promising new class that have demonstrated efficacy with a favorable safety profile in clinical trials. Utilizing a mix of didactic presentations and prerecorded patient videos, this activity based on a live symposium will explore current and emerging treatments and guidelines for UC and CD. The faculty panel provides a thorough examination of current and emerging JAK inhibitors, as well as insight into patient-centered, treat-to-target management approaches in IBD. Upon completion of this activity, participants should be better able to: Examine the burden of illness and unmet needs in patients with inflammatory bowel disease, Summarize efficacy and safety data related to current and emerging JAK inhibitors for the treatment of Crohn's disease (CD) and ulcerative colitis (UC), Treat CD and UC in accordance with current evidence and guidelines, recognizing the role of non–anti-TNF therapies in inducing and maintaining remission in patients with moderate to severe disease, Incorporate JAK inhibitors into treatment plans for individual patients with CD or UC, recognizing the importance of achieving therapeutic targets and a patient-centered approach to care.

Go online to PeerView.com/QDR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has brought substantial advances in the management of IBD. Nevertheless, under current therapeutic options, half of patients with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD) fail to achieve sustained remission. After years of IBD treatment dominated by monoclonal antibodies, we are currently witnessing promising developments of small molecules for UC and CD. Among them, Janus kinase (JAK) inhibitors are a promising new class that have demonstrated efficacy with a favorable safety profile in clinical trials. Utilizing a mix of didactic presentations and prerecorded patient videos, this activity based on a live symposium will explore current and emerging treatments and guidelines for UC and CD. The faculty panel provides a thorough examination of current and emerging JAK inhibitors, as well as insight into patient-centered, treat-to-target management approaches in IBD. Upon completion of this activity, participants should be better able to: Examine the burden of illness and unmet needs in patients with inflammatory bowel disease, Summarize efficacy and safety data related to current and emerging JAK inhibitors for the treatment of Crohn's disease (CD) and ulcerative colitis (UC), Treat CD and UC in accordance with current evidence and guidelines, recognizing the role of non–anti-TNF therapies in inducing and maintaining remission in patients with moderate to severe disease, Incorporate JAK inhibitors into treatment plans for individual patients with CD or UC, recognizing the importance of achieving therapeutic targets and a patient-centered approach to care.

Go online to PeerView.com/QDR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has brought substantial advances in the management of IBD. Nevertheless, under current therapeutic options, half of patients with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD) fail to achieve sustained remission. After years of IBD treatment dominated by monoclonal antibodies, we are currently witnessing promising developments of small molecules for UC and CD. Among them, Janus kinase (JAK) inhibitors are a promising new class that have demonstrated efficacy with a favorable safety profile in clinical trials. Utilizing a mix of didactic presentations and prerecorded patient videos, this activity based on a live symposium will explore current and emerging treatments and guidelines for UC and CD. The faculty panel provides a thorough examination of current and emerging JAK inhibitors, as well as insight into patient-centered, treat-to-target management approaches in IBD. Upon completion of this activity, participants should be better able to: Examine the burden of illness and unmet needs in patients with inflammatory bowel disease, Summarize efficacy and safety data related to current and emerging JAK inhibitors for the treatment of Crohn's disease (CD) and ulcerative colitis (UC), Treat CD and UC in accordance with current evidence and guidelines, recognizing the role of non–anti-TNF therapies in inducing and maintaining remission in patients with moderate to severe disease, Incorporate JAK inhibitors into treatment plans for individual patients with CD or UC, recognizing the importance of achieving therapeutic targets and a patient-centered approach to care.

David T. Rubin, MD, from the University of Chicago, is the chair of the Advances in Inflammatory Bowel Diseases Regional Meeting in Chicago, Illinois. In this podcast, he provides highlights of the upcoming meeting and explains key concepts for clinicians to implement into practice.

Medicine Grand Rounds Friday, June 16, 2017 David T. Rubin, MD, FACG, AGAF, FACP, FASGE The Joseph B. Kirsner Professor of Medicine Chief, Gastroenterology, Hepatology and Nutrition Co-Director, Digestive Diseases Center University of Chicago Medicine

Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis, according to a study in the June CGH. Dr. Kuemmerle speaks to the author of an accompanying editorial, Dr. David T. Rubin

Guest: Imtiaz Alam, MD Host: David T. Rubin, MD The number of new cases of hepatitis C has declined significantly since its peak in the late 1980s. But now, two decades later, we’re seeing the manifestation of long-term complications from this chronic disease. Dr. Imtiaz Alam, founding medical director of the Austin Hepatitis Center in Austin, Tex., examines the clinical obstacles that often occur when treating a large volume of patients with complex cases of hepatitis C. Looking to the future, how can screening and other prevention mechanisms aid in fighting the pervasive impact of this disease? Find out more with host Dr. David Rubin.

Guest: Carla Ginsburg, MD, MPH Host: David T. Rubin, MD Annually, Medicare payments to physicians are modified using the sustainable growth rate formula, or “SGR”. Recently, the formula mandated cuts to physicians in recent years; and only through quick congressional fixes were these cuts avoided. With payments expected to drop more than 40 percent in the next eight years, can the SGR truly be part of an effective solution to our healthcare crisis? What is the formula, and what impact will it continually have on patient care? Gastroenterologist, and Assistant Clinical Professor of Medicine at Harvard Medical School speaks with your host, Dr. David Rubin.

Guest: Imtiaz Alam, MD Host: David T. Rubin, MD We are developing increasingly effective therapies for patients with chronic hepatitis C, yet many physicians who treat a high volume of these patients are struggling to maintain economically viable strategies for providing care. Is treatment of hepatitis C becoming a money-losing proposition? Can a few simple adjustments revitalize your clinic's financial outlook? Dr. Imtiaz Alam, founding medical director of the Austin Hepatitis Center in Austin, Tex., joins host Dr. David Rubin.

Guest: Imtiaz Alam, MD Host: David T. Rubin, MD We are developing increasingly effective therapies for patients with chronic hepatitis C, yet many physicians who treat a high volume of these patients are struggling to maintain economically viable strategies for providing care. Is treatment of hepatitis C becoming a money-losing proposition? Can a few simple adjustments revitalize your clinic's financial outlook? Dr. Imtiaz Alam, founding medical director of the Austin Hepatitis Center in Austin, Tex., joins host Dr. David Rubin.

Guest: Carla Ginsburg, MD, MPH Host: David T. Rubin, MD Annually, Medicare payments to physicians are modified using the sustainable growth rate formula, or “SGR”. Recently, the formula mandated cuts to physicians in recent years; and only through quick congressional fixes were these cuts avoided. With payments expected to drop more than 40 percent in the next eight years, can the SGR truly be part of an effective solution to our healthcare crisis? What is the formula, and what impact will it continually have on patient care? Gastroenterologist, and Assistant Clinical Professor of Medicine at Harvard Medical School speaks with your host, Dr. David Rubin.

Guest: Imtiaz Alam, MD Host: David T. Rubin, MD The number of new cases of hepatitis C has declined significantly since its peak in the late 1980s. But now, two decades later, we’re seeing the manifestation of long-term complications from this chronic disease. Dr. Imtiaz Alam, founding medical director of the Austin Hepatitis Center in Austin, Tex., examines the clinical obstacles that often occur when treating a large volume of patients with complex cases of hepatitis C. Looking to the future, how can screening and other prevention mechanisms aid in fighting the pervasive impact of this disease? Find out more with host Dr. David Rubin.